When was NeuroBo Founded?
NeuroBo Pharmaceuticals was founded in July 2017
Where is NeuroBo Incorporated?
NeuroBo Pharmaceuticals was incorporated under the laws of the State of Delaware in July 2017
Where is NeuroBo Located?
NeuroBo Pharmaceuticals’ principal offices are located at 200 Berkley Street, 19th Floor, Boston, Massachusetts 02116
When did NeuroBo begin trading as a public company?
NeuroBo became a publicly traded company on December 31, 2019 in connection with the reverse merger with Gemphire Therapeutics, Inc. (previously Nasdaq: GEMP), at which time the company changed its ticker symbol to NRBO.
How did NeuroBo become a public company?
On July 24, 2019, NeuroBo Therapeutics and its former shareholders entered into an exchange agreement with Gemphire Pharmaceuticals (“Gemphire”). Under the agreement, Gemphire changed its name to NeuroBo Pharmaceuticals and then acquired all of the outstanding shares of NeuroBo Therapeutics in exchange for newly issued shares of NeuroBo Pharmaceuticals, resulting in NeuroBo Therapeutics becoming a wholly-owned subsidiary. The transaction closed on December 30, 2019 and resulted in a publicly traded biopharmaceutical company focused on advancing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.
If I was a stockholder of NeuroBo Pharmaceuticals, Inc. when it traded under the name Gemphire Therapeutics, prior to the merger, what happened to my stock?
Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, email@example.com
What can I do with the Contingent Value Rights (CVR)?
Prior to completion of the Merger, Gemphire entered into the CVR Agreement, which the Company assumed in the Merger and amended in March 2021. Under the amended CVR Agreement, the holders of Gemphire shares at the time of the Merger will receive (i) 80% of the proceeds from any grant, sale, or transfer of rights to Gemcabene as a treatment for cardiovascular conditions and (ii) 10% of the proceeds from any future grant, sale, or transfer of rights to Gemcabene as a treatment for any indication outside of treating cardiometabolic conditions, including COVID-19. CVRs are not transferrable. You can access the full CVR Agreement here
and the CVR Agreement amendment here
Where can I access Form 8937 in connect with the merger?
You can access Form 8937 in the Financial section of NeuroBo’s website here
When did NeuroBo Pharmaceuticals acquire ANA Therapeutics and what were the terms of the transaction?
NeuroBo Pharmaceuticals acquired privately held biopharmaceutical company, ANA Therapeutics (ANA), on December 31, 2020. Under the terms of the acquisition agreement, ANA became a wholly-owned subsidiary of NeuroBo and ANA equity holders were issued an aggregate of approximately 3.24 million shares of NeuroBo common stock, representing 19.7% of NeuroBo's outstanding shares. ANA shareholders will receive additional payments (in cash or NeuroBo common shares) upon the achievement of various development and net sales milestones for ANA001 and will also receive royalties based on net sales of ANA001.
Where is NeuroBo Pharmaceuticals’ stock traded?
NeuroBo Pharmaceuticals’ stock is traded on the Nasdaq Capital Markets under the symbol NRBO.
When is NeuroBo’s fiscal year end?
NeuroBo’s fiscal year end is December 31st.
What is NeuroBo’s CUSIP number?
NeuroBo’s CUSIP number is 64132R 10 7.
Who is NeuroBo’s stock transfer agent?
NeuroBo’s stock transfer agent is AST Financial, 6201 15th Avenue, Brooklyn, NY 11219. You may reach an AST representative by dialing (800) 937-5449 or by e-mail at firstname.lastname@example.org.
Who do I contact if I need to change the name of the registered holder, etc.?
For lost stock certificates or to make changes to the name of the registered holder, please contact NeuroBo’s stock transfer agent, AST Financial.
How can I buy or sell shares of NeuroBo stock?
You can buy or sell shares of NeuroBo Pharmaceuticals (Nasdaq: NRBO) through a licensed stockbroker or by using an online account.
Does NeuroBo pay dividends?
NeuroBo does not currently pay any cash or other dividends. Management anticipates that it will retain all available funds and any future earnings, if any, for use in the operation of the business.
Who are NeuroBo’s independent auditors?
NeuroBo’s independent auditors are BDO USA, LLP, located in Boston, Massachusetts.
Who is NeuroBo’s legal counsel?
NeuroBo’s legal counsel is Honigman LLP.
How many employees does NeuroBo have?
As of March 30, 2020, NeuroBo has 12 full-time employees.
Where can I get the latest corporate news and financial reports?
You can access the latest corporate news through the Press Release section of the NeuroBo website here
and you can access financial information in the SEC Filing section of the NeuroBo website here
How can I receive email alerts from NeuroBo?
You can sign up for email alerts from NeuroBo here
How can I contact NeuroBo for additional questions about the company?
For additional information on NeuroBo, you can reach out to the Investor Relations contact: Michael Miller, Rx Communications Group, LLC, email@example.com